Conditions are getting a bit more challenging for the drugmaker.

INDIANAPOLIS (AP) — Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two key drugs that missed expectations. The drugmaker ...

(Reuters) -Eli Lilly missed Wall Street estimates for third-quarter profit on Wednesday, hurt by higher manufacturing costs ...

Eli Lilly shares slid after the drugmaker reported disappointing quarterly results, with sales of its popular diabetes and anti-obesity drugs lower than expected. Lilly said inventory decreases by ...

A 58-year-old nurse from Scotland has died after taking two doses of weight-loss drug tirzepatide, also known as Mounjaro or ...

Deutsche Bank lowered the firm’s price target on Eli Lilly (LLY) to $1,015 from $1,025 and keeps a Buy rating on the shares following the Q3 report. Published first on TheFly – the ultimate ...

It's shaping up to be a tough period for Eli Lilly and Company (NYSE ... and see if there has been any change to expectations for the business. With this in mind, we've gathered the latest ...

Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from ...

Everyone knows that big pharma companies like Eli Lilly (NYSE: LLY) need to get regulators to agree that their medicines are safe and effective before they can make any money. But regulators aren ...